AR117389A2 - Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en métodos para tratar cáncer - Google Patents
Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en métodos para tratar cáncerInfo
- Publication number
- AR117389A2 AR117389A2 ARP190100158A ARP190100158A AR117389A2 AR 117389 A2 AR117389 A2 AR 117389A2 AR P190100158 A ARP190100158 A AR P190100158A AR P190100158 A ARP190100158 A AR P190100158A AR 117389 A2 AR117389 A2 AR 117389A2
- Authority
- AR
- Argentina
- Prior art keywords
- pal
- variant
- phenylalanine
- compositions
- wild
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una variante de fenilalaninamoniacoliasas (PAL) producida por procariontes, en donde dicha variante de PAL de procariontes tiene mayor actividad convertidora de fenilalanina y/o reducida inmunogenicidad, comparada con una PAL de tipo silvestre. La presente provee composiciones de PAL de procarionte y sus fragmentos, mutantes, variantes o análogos biológicamente activos, así como métodos para la producción, purificación y uso de dichas composiciones con fines terapéuticos, incluso para el tratamiento de cáncer. Reivindicación 1: Una composición farmacéutica caracterizada porque comprende una variante de fenilalaninamoniacoliasa de procariontes (PAL) y un portador farmacéuticamente aceptable, en donde dicha variante PAL tiene mayor actividad convertidora de fenilalanina y/o reducida inmunogenicidad, comparada con una PAL de tipo salvaje, en donde el portador farmacéuticamente aceptable comprende un estabilizador. Reivindicación 4: La composición farmacéutica de la reivindicación 3, caracterizada porque dicha variante de PAL en donde la variante de PAL es de Anabaena variabilis (AvPAL). Reivindicación 23: Un método para tratar cáncer, caracterizado porque comprende administrar a un paciente una cantidad terapéuticamente efectiva de una composición farmacéutica que comprende una variante de PAL y un portador farmacéuticamente aceptable, en donde dicha variante de PAL: a) tiene mayor actividad convertidora de fenilalanina y/o a reducida inmunogenicidad, comparada con una PAL de tipo salvaje; y b) es efectiva para reducir la concentración de fenilalanina en sangre, suero o plasma del paciente en un rango de menos del nivel de detección a entre 20 mM y 60 mM.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6612507P | 2007-08-17 | 2007-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117389A2 true AR117389A2 (es) | 2021-08-04 |
Family
ID=40363135
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103596A AR067972A1 (es) | 2007-08-17 | 2008-08-15 | Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en metodos para tratar cancer |
| ARP190100158A AR117389A2 (es) | 2007-08-17 | 2019-01-24 | Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en métodos para tratar cáncer |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103596A AR067972A1 (es) | 2007-08-17 | 2008-08-15 | Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en metodos para tratar cancer |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US7560263B2 (es) |
| EP (1) | EP2175875B1 (es) |
| JP (1) | JP5584120B2 (es) |
| CN (1) | CN101803492B (es) |
| AR (2) | AR067972A1 (es) |
| AU (1) | AU2008289549B2 (es) |
| BR (2) | BR122018072594B8 (es) |
| CA (1) | CA2687028C (es) |
| CL (1) | CL2008002390A1 (es) |
| CY (1) | CY1118222T1 (es) |
| DK (1) | DK2175875T3 (es) |
| ES (1) | ES2602618T3 (es) |
| HR (1) | HRP20161474T1 (es) |
| HU (1) | HUE029510T4 (es) |
| LT (1) | LT2175875T (es) |
| MX (1) | MX2009012261A (es) |
| PE (1) | PE20090605A1 (es) |
| PL (1) | PL2175875T3 (es) |
| PT (1) | PT2175875T (es) |
| RU (2) | RU2009141987A (es) |
| SI (1) | SI2175875T1 (es) |
| TW (1) | TWI418787B (es) |
| WO (1) | WO2009025760A2 (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7560263B2 (en) * | 2007-08-17 | 2009-07-14 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| EP2219602A1 (en) * | 2007-11-15 | 2010-08-25 | Amgen, Inc | Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration |
| WO2010014225A2 (en) | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
| WO2011078667A2 (en) | 2009-12-22 | 2011-06-30 | Dsm Ip Assets B.V. | Method of finding a biocatalyst having ammonia lyase activity |
| CN106834261B (zh) | 2010-02-04 | 2022-02-18 | 生物马林药物股份有限公司 | 原核苯丙氨酸解氨酶变异体的组合物以及利用其组合物的方法 |
| US20120148559A1 (en) | 2010-12-01 | 2012-06-14 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
| US20150246083A1 (en) * | 2012-07-27 | 2015-09-03 | University Of North Texas | Genetically modified probiotic for the treatment of phenylketonuria (pku) disease |
| MX366196B (es) | 2013-04-18 | 2019-07-01 | Codexis Inc | Polipeptidos diseñados de fenilalanina amonio liasa. |
| EP3071515A2 (en) | 2013-11-18 | 2016-09-28 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| RU2736495C2 (ru) | 2014-04-01 | 2020-11-17 | Рубиус Терапьютикс, Инк. | Способ и композиции для иммуномодуляции |
| HUE056444T2 (hu) | 2014-04-16 | 2022-02-28 | Codexis Inc | Génmódosított tirozin-ammónia-liáz |
| CN106456723B (zh) | 2014-04-29 | 2021-03-09 | 康达医药科技有限公司 | 采用精氨酸酶i调节免疫系统的方法和组合物 |
| WO2016008886A1 (en) * | 2014-07-14 | 2016-01-21 | Danmarks Tekniske Universitet | Processes for the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity |
| US20170360900A1 (en) | 2014-12-22 | 2017-12-21 | Codexis, Inc. | Human alpha-galactosidase variants |
| EP3491008A2 (en) | 2016-07-26 | 2019-06-05 | BioMarin Pharmaceutical Inc. | Novel adeno-associated virus capsid proteins |
| IT201600086488A1 (it) * | 2016-08-22 | 2018-02-22 | St Microelectronics Srl | Dispositivo a semiconduttore e corrispondente procedimento |
| WO2018148633A1 (en) | 2017-02-13 | 2018-08-16 | Codexis, Inc. | Engineered phenylalanine ammonia lyase polypeptides |
| EP3790627A2 (en) | 2018-05-09 | 2021-03-17 | BioMarin Pharmaceutical Inc. | Methods of treating phenylketonuria |
| TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| US10900055B2 (en) | 2018-06-12 | 2021-01-26 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| EP3893860A4 (en) | 2018-12-14 | 2023-03-29 | Codexis, Inc. | ENGINEERED TYROSINE AMMONIA LYASE |
| US11427813B2 (en) | 2018-12-20 | 2022-08-30 | Codexis, Inc. | Human alpha-galactosidase variants |
| MA54936A (fr) | 2019-02-14 | 2021-12-22 | Som Innovation Biotech S A | Triamtérène ou nolatrexed destinés à être utilisés dans le traitement de la phénylcétonurie |
| WO2021026393A1 (en) * | 2019-08-07 | 2021-02-11 | Rakuten Medical, Inc. | Cetuximab-ir700 conjugate compositions |
| US11987823B2 (en) | 2019-08-30 | 2024-05-21 | Societe Des Produits Nestle S.A. | Engineered lipase variants |
| CA3165484A1 (en) | 2019-12-20 | 2021-06-24 | Codexis, Inc. | Engineered acid alpha-glucosidase variants |
| WO2021158686A1 (en) | 2020-02-04 | 2021-08-12 | Codexis, Inc. | Engineered leucine decarboxylases |
| AR122409A1 (es) | 2020-04-03 | 2022-09-07 | Biomarin Pharm Inc | Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas |
| CA3191867A1 (en) | 2020-08-28 | 2022-03-03 | Codexis, Inc. | Engineered protease variants |
| CA3191900A1 (en) | 2020-08-28 | 2022-03-03 | Codexis, Inc. | Engineered amylase variants |
| EP4341394A4 (en) | 2021-05-19 | 2025-04-09 | BioMarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia lyase and methods for treating adolescent patients |
| TW202313969A (zh) | 2021-05-21 | 2023-04-01 | 美商克迪科思股份有限公司 | 經工程化的甲硫胺酸γ解離酶變異體 |
| CN115873837A (zh) * | 2022-11-18 | 2023-03-31 | 安徽盈科生物科技有限公司 | 高表达的新型的苯丙氨酸解氨酶 |
| CN118931888A (zh) * | 2023-05-09 | 2024-11-12 | 重庆派金生物科技有限公司 | 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐 |
| GB202307239D0 (en) | 2023-05-15 | 2023-06-28 | Evox Therapeutics Ltd | Gene therapies for Phenylketonuria |
| WO2025106759A1 (en) | 2023-11-17 | 2025-05-22 | Biomarin Pharmaceutical Inc. | Conjugates of phenylalanine ammonia-lyase and poegma and methods for their use |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4252822A (en) * | 1979-12-26 | 1981-02-24 | Children's Hospital Medical Center | Method for treating phenylketonuria |
| US4562151A (en) * | 1983-09-06 | 1985-12-31 | Monsanto Company | Stabilization of L-phenylalanine ammonia-lyase enzyme |
| US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| US5212939A (en) * | 1991-12-04 | 1993-05-25 | Pratt Jr John M | Marine mooring swivel fitting |
| JP2930723B2 (ja) * | 1992-11-19 | 1999-08-03 | アンティキャンサー インコーポレーテド | 抗メチオニン化学療法における抗腫瘍薬としてのメチオニナーゼの使用 |
| ES2287926T3 (es) | 1992-12-04 | 2007-12-16 | Me Medical Enzymes Ag | Glutaminasa manipulada geneticamente y su uso en terapia. |
| DK75593D0 (es) * | 1993-06-25 | 1993-06-25 | Novo Nordisk As | |
| KR0164757B1 (ko) * | 1995-06-13 | 1999-01-15 | 김광호 | 공조장치의 살균집진장치와 그 방법 |
| DK0851925T3 (da) * | 1995-09-21 | 2005-11-28 | Genentech Inc | Humane Væksthormonvarianter |
| CU22585A1 (es) | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune. |
| US6548644B1 (en) | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
| US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
| US5981239A (en) | 1997-09-24 | 1999-11-09 | Great Lakes Chemical Corp. | Synthesis of optically active phenylalanine analogs using Rhodotorula graminis |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| US6461849B1 (en) | 1998-10-13 | 2002-10-08 | Novozymes, A/S | Modified polypeptide |
| US6686164B1 (en) | 1998-10-30 | 2004-02-03 | Novozymes A/S | Low allergenic protein variants |
| IL138990A0 (en) * | 1999-02-12 | 2001-11-25 | Biostream Inc | Matrices for drug delivery and methods for making and using the same |
| US6586398B1 (en) * | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| AU2001257032A1 (en) | 2000-04-14 | 2001-10-30 | University Of South Carolina Research Foundation | Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase |
| US6967097B2 (en) | 2000-07-24 | 2005-11-22 | Pcbu Services, Inc. | Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same |
| US6939941B2 (en) * | 2001-09-12 | 2005-09-06 | Toray Fine Chemicals Co., Ltd. | Preparation of polysulfide compositions |
| EP1476563B1 (en) | 2002-02-26 | 2008-09-17 | E.I. Du Pont De Nemours And Company | Method for the recombination of genetic elements |
| CA2506026A1 (en) | 2002-11-14 | 2004-05-27 | The Scripps Research Institute | Crystalline form of fatty acid amine hydrolase (faah) |
| US7553653B2 (en) | 2004-09-17 | 2009-06-30 | Biomarin Pharmaceutical Inc. | Variants and chemically-modified variants of phenylalanine ammonia-lyase |
| US20090038023A1 (en) | 2005-03-10 | 2009-02-05 | Verenium Corporation | Lyase Enzymes, Nucleic Acids Encoding Them and Methods For Making and Using Them |
| US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| DE102006032167B4 (de) | 2006-07-12 | 2014-11-27 | Evonik Degussa Gmbh | Verfahren zur Herstellung von Triallylisocyanurat (TAIC) |
| US20090011400A1 (en) | 2006-12-01 | 2009-01-08 | The Salk Institute for Biological Studies and The Regents of the University of California | Substrate switched ammonia lyases and mutases |
| US7560263B2 (en) | 2007-08-17 | 2009-07-14 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| WO2010014225A2 (en) | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
-
2008
- 2008-04-22 US US12/107,731 patent/US7560263B2/en active Active
- 2008-04-22 US US12/107,736 patent/US7537923B2/en active Active
- 2008-08-14 CL CL2008002390A patent/CL2008002390A1/es unknown
- 2008-08-15 LT LTEP08795357.6T patent/LT2175875T/lt unknown
- 2008-08-15 WO PCT/US2008/009765 patent/WO2009025760A2/en not_active Ceased
- 2008-08-15 PT PT87953576T patent/PT2175875T/pt unknown
- 2008-08-15 HU HUE08795357A patent/HUE029510T4/en unknown
- 2008-08-15 MX MX2009012261A patent/MX2009012261A/es active IP Right Grant
- 2008-08-15 ES ES08795357.6T patent/ES2602618T3/es active Active
- 2008-08-15 PE PE2008001395A patent/PE20090605A1/es active IP Right Grant
- 2008-08-15 BR BR122018072594A patent/BR122018072594B8/pt active IP Right Grant
- 2008-08-15 DK DK08795357.6T patent/DK2175875T3/en active
- 2008-08-15 JP JP2010521043A patent/JP5584120B2/ja active Active
- 2008-08-15 CA CA2687028A patent/CA2687028C/en active Active
- 2008-08-15 AU AU2008289549A patent/AU2008289549B2/en active Active
- 2008-08-15 AR ARP080103596A patent/AR067972A1/es not_active Application Discontinuation
- 2008-08-15 CN CN200880016488.XA patent/CN101803492B/zh active Active
- 2008-08-15 RU RU2009141987/15A patent/RU2009141987A/ru not_active Application Discontinuation
- 2008-08-15 PL PL08795357T patent/PL2175875T3/pl unknown
- 2008-08-15 TW TW097131325A patent/TWI418787B/zh active
- 2008-08-15 RU RU2012134838/15A patent/RU2553343C2/ru active
- 2008-08-15 HR HRP20161474TT patent/HRP20161474T1/hr unknown
- 2008-08-15 BR BRPI0811589A patent/BRPI0811589B8/pt active IP Right Grant
- 2008-08-15 EP EP08795357.6A patent/EP2175875B1/en active Active
- 2008-08-15 SI SI200831703A patent/SI2175875T1/sl unknown
-
2009
- 2009-04-09 US US12/421,557 patent/US7790433B2/en active Active
-
2010
- 2010-07-09 US US12/833,911 patent/US20100278802A1/en not_active Abandoned
-
2016
- 2016-11-10 CY CY20161101163T patent/CY1118222T1/el unknown
-
2019
- 2019-01-24 AR ARP190100158A patent/AR117389A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR117389A2 (es) | Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en métodos para tratar cáncer | |
| AR110834A2 (es) | MOLÉCULA DE UNA VARIANTE AISLADA DE FENILALANINA AMONIACOLIASA DE ANABAENA VARIABILIS (AvPal) | |
| BRPI0610093A2 (pt) | composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente | |
| BR0014710A (pt) | Métodos para o tratamento de dor | |
| ATE506375T1 (de) | Gegen das c5-komponent des komplementsystems gerichtete antikörper und deren verwendung | |
| NZ587105A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| BRPI0411856A (pt) | composições e métodos para o aumento da atividade de telomerase | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| WO2009044392A3 (en) | Novel sirna structures | |
| NZ602471A (en) | Antagonists of activin-actriia and uses for increasing red blood cell levels | |
| BRPI0518793A2 (pt) | mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica | |
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| NZ578928A (en) | Methods to increase mobility of hematopoietic stem cells by use of a lipopeptide compound and treatment of associated diseases | |
| RU2015153735A (ru) | Гепарансульфаты | |
| EA201170917A1 (ru) | Ген, кодирующий мутантную глюкокиназу человека, кодируемый им фермент, рекомбинантные векторы и хозяева, фармацевтические композиции и их применения, способы лечения и предупреждения болезней | |
| IL165858A (en) | Pharmaceutical preparation for treating human malignancies with arginine deprivation and uses thereof | |
| MX341317B (es) | Proteinas de elastasa recombinantes y metodos de fabricacion y uso de las mismas. | |
| EP2114431A4 (en) | COMPOSITION WITH ARAZYM FOR THE PREVENTION AND TREATMENT OF CANCER | |
| MX2013008374A (es) | Apolipoproteina a-iv como un peptido antidiabetico. | |
| WO2004043373A3 (en) | Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme | |
| CA2632207C (en) | Use of calcitonin for the treatment of ra | |
| EA200700178A1 (ru) | Пептид, обладающий стресспротекторным действием, фармацевтическая композиция на его основе и способ ее применения | |
| MX2011007108A (es) | Incrementadores de angiogenesis generados por derrame cerebral y usos de los mismos. | |
| TW200501946A (en) | Pharmaceutical composition for the treatment of schizophrenia in a patient with overweight | |
| MX2022011171A (es) | Compuestos con actividad inmunomodulatoria y usos terapeuticos de estos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |